Cardiol is planning a Phase 2 international trial of acute myocarditis, the most common cause of sudden cardiac death in people under 35 years of age.

Committed to conquering a serious condition that affects more than 26 million people globally.

Our pharmaceutically produced cannabidiol products are ultra-pure and are formulated specifically for medical purposes.